Video Roundtable: Industry Leaders Talk COVID-19, Strategy And The Year Ahead
Accord, mAbxience, PharmEvo And Sandoz Leaders Discuss Priorities For The Sector
Executive Summary
In this exclusive video roundtable discussion, leaders from across the off-patent industry talk about the COVID-19 pandemic and the industry’s response, as well as highlighting key regulatory, policy and strategic developments that may have flown under the radar in the past year.
You may also be interested in...
Accord Takes A Trio Of Awards
Accord Healthcare took home a trio of prizes at the Global Generics & Biosimilars Awards 2020, with other winners including Alvogen, Aurobindo, Dr Reddy’s, Eurofarma, Insud Pharma, Macleods, Pinsent Masons, Samsung Bioepis, Sandoz, Stada and Zentiva.
Bio-Thera Ventures Outside China With European Bevacizumab Filing
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
EU Pharma Strategy Will Remove Barriers And Bolster Competition
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: